APPLYING GATA3 IN DIFFERENTIATING UROTHELIAL CARCINOMA FROM PROSTATIC ADENOCARCINOMA: AN IMMUNOHISTOCHEMICAL STUDY
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i12.28232Keywords:
GATA 3, Urothelial carcinoma, Prostatic adenocarcinoma, Immunohistochemical expressionAbstract
Objectives: Urothelial carcinoma and prostatic adenocarcinoma are the most common tumors of genitourinary system. Both tumors can demonstrate a broad morphology or present as poorly differentiated carcinoma occurring in urinary bladder or prostate or both organs that raise the suspicion of a locally extending or metastatic carcinoma from either organs. Accurate distinction between these tumors is mandatory because of different tumor biology and therapeutic protocols. In equivocal tumor morphology, the primary option is to use immunohistochemical panel in surgical pathology that includes differentiation markers that will assist pathologists to avoid misdiagnosis. The aim of this study is immunohistochemical evaluation of GATA3 in urothelial carcinoma and prostatic adenocarcinoma with correlation to different clinicopathological parameters.
Methods: We used formalin-fixed paraffin-embedded tissue blocks from 51 patients of urothelial carcinoma and 15 patients of prostatic adenocarcinoma including different grades, stages, and types. Monoclonal antibody for GATA3 was used for immunohistochemical staining of tissue sections, and GATA3 expression was semi-quantitatively scored using H-score method.
Results: Of 51 urothelial carcinomas, 96% were GATA3 positive with a mean H-score = 212. No correlation between GATA3 expression and clinicopathological parameters includes grade and stage. Lower GATA3 expression was noted in urothelial carcinoma variants. All of prostatic adenocarcinoma cases did not show GATA3 reactivity.
Conclusion: GATA3 reactivity is a reliable factor to confirm diagnosis of urothelial carcinoma and exclude prostatic adenocarcinoma. The routine use of GATA3 as differentiation marker for urothelial carcinoma may be advocated based on the results of this study.
Downloads
References
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A Systematic analysis for the global burden of disease study. JAMA Oncol 2017;3:524-48.
Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011;306:737-45.
Reulen RC, Kellen E, Buntinx F, Brinkman M, Zeegers MP. A meta-analysis on the association between bladder cancer and occupation. Scand J Urol Nephrol Suppl 2008;218:64-78.
Abol-Enein H. Infection: is it a cause of bladder cancer. Scand J Urol Nephrol Suppl 2008;218:79-84.
Minakshi G, Jyoti D, Rakesh KM, Harish D. Therapies in cancer treatment: An overview. Int J Pharm Pharm Sci 2015;7:1-9.
Amin MB, Smith SC, Reuter VE, Epstein JI, Grignon DJ, Hansel DE, et al. Update for the practicing pathologist: The international consultation on urologic disease-European association of urology consultation on bladder cancer. Mod Pathol 2015;28:612-30.
Amin MB. Histological variants of urothelial carcinoma: Diagnostic, therapeutic and prognostic implications. Modern Pathol 2009;22:S96-118.
Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: A meta-analysis. Cancer 2003;97:1894-903.
Zhu C, Luong R, Zhuo M, Johnson DT, McKenney JK, Cunha GR, et al. Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate. J Biol Chem 2011;286:33478-88.
Hori S, Blanchet JS, Mcloughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: A review of the emerging role of proPSAs in lhe detection and management of early prostate cancer. BJU Int 2013;112:717-28.
Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi- Galluzzi C, et al. A contemporary prostate cancer grading system: A Validated alternative to the gleason score. Eur Urol 2016;69:428-35.
Yamashita M, Ukai-Tadenuma M, Miyamoto T, Sugaya K, Hosokawa H, Hasegawa A, et al. Essential role of GATA3 for the maintenance of Type 2 helper T (Th2) cytokine production and chromatin remodeling at the Th2 cytokine gene loci. J Biol Chem 2004;279:26983-90.
Mohd KS, Hassan MA, Azmin W, Dharmaraj S. A review of potential anticancers from antimicrobial peptides. Int J Pharm Pharm Sci 2015;7:19-24.
McCleskey BC, Penedo TL, Zhang K, Hameed O, Siegal GP, Wei S, et al. GATA3 expression in advanced breast cancer: Prognostic value and organ-specific relapse. Am J Clin Pathol 2015;144:756-63.
Li Y, Ishiguro H, Kawahara T, Miyamoto Y, Izumi K, Miyamoto H, et al. GATA3 in the urinary bladder: Suppression of neoplastic transformation and down-regulation by androgens. Am J Cancer Res 2014;4:461-73.
Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, Takizawa T, et al. Sex steroid hormone receptors in human thymoma. J Clin Endocrinol Metab 2003;88:2309-17.
Oh WJ, Chung AM, Kim JS, Han JH, Hong SH, Lee JY, et al. Differential immunohistochemical profiles for distinguishing prostate carcinoma and urothelial carcinoma. J Pathol Transl Med 2016;50:345 54.
Liu H, Shi J, Wilkerson ML, Lin F. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: A useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol 2012;138:57-64.
Clark BZ, Beriwal S, Dabbs DJ, Bhargava R. Semiquantitative GATA- 3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas. Am J Clin Pathol 2014;142:64-71.
Leivo MZ, Elson PJ, Tacha DE, Delahunt B, Hansel DE. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma. Pathology 2016;48:543-9.
Higgins JP, Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu SX, et al. Placental S100 (S100P) and GATA3: Markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol 2007;31:673-80.
Chang A, Amin A, Gabrielson E, Illei P, Roden RB, Sharma R, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol 2012;36:1472-6.
Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, et al. GATA3: A multispecific but potentially useful marker in surgical pathology: A systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol 2014;38:13-22.
Rao Q, Williamson SR, Lopez-Beltran A, Montironi R, Huang W, Eble JN, et al. Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: Extended immunohistochemical profiles emphasizing novel markers. Mod Pathol 2013;26:725-32.
Helmy NA, Khalil HK, Kamel NN, AboelFadl DM. Role of GATA3, CK7, CK20 and CK14 in distinguishing urinary bladder squamous cell carcinoma and urothelial carcinoma with squamous differentiation. Egypt J Pathol 2015;35:133-8.
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: Prostate and bladder tumours. Eur Urol 2016;70:106 19.26.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
